RAG1 and neoplasm: Anti-angiogenic agents can facilitate CAR-T cell transit to target tumor sites possibly by targeting the repair of “spontaneous” DNA double-strand breaks caused by recombination-activating gene 1/2 (RAG1/2) and/or reactive oxygen species (ROS), thereby augmenting the therapeutic efficacy of standard cytotoxic drugs (Dasgupta et al., 2018).